|
|
|
|
|
|
|
to the publisher. Word processing has revolutionized this approach and will revolutionize it further in the next couple of years. This is the same revolution that totally changes the drug development process, facilitates it, and further facilitates the review of the database presented for review. All phases will undergo radical change and we will be better for it. This is a most exciting era and one that will be both fun and worthwhile to live through. |
|
|
|
 |
|
|
|
|
1. A. Toffler, Future Shock. Random House, New York, 1970. |
|
|
|
|
|
|
|
|
2. R. J. Myerburg, K. M. Kessler, I. Kiem, K. C. Pefkaros, C. A. Conde, D. Cooper, and A. Castellanos. Relationship Between Plasma Levels of Procainamide, Suppression of Premature Ventricular Complexes and Prevention of Recurrent Ventricular Tachycardia. Circulation 64: 280289, 1981. |
|
|
|
|
|
|
|
|
3. The SOLVD Investigators. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. New Engl. J. Med. 325: 293302, 1991. |
|
|
|
|
|
|
|
|
4. Scandinavian Simvastatin Survival Study Group. Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 13831389, 1994. |
|
|
|
|
|
|
|
|
5. M. Packer, M. Gheorghiade, J. B. Young, P. J. Constantini, K. F. Adams, R. J. Cody, L. K. Smith, L. van Voorhees, L. A. Gourley, and M. K. Jolly for the RADIANCE Study. Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors. New Engl. J. Med. 329: 17, 1993. |
|
|
|
|
|
|
|
|
6. A. M. Feldman, M. R. Bristow, W. W. Parmley, P. E. Carson, C. J. Pepine, E. M. Gilbert, J. E. Strobeck, G. H. Hendrix, E. R. Powers, R. P. Bain, and B. G. White for the Vesnarinone Study Group. Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure. New Engl. J. Med. 329: 149155, 1993. |
|
|
|
|
|